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   ABSTRACT   
  Background      Remission is the established goal in 
rheumatoid arthritis (RA) treatment. Although originally 
deﬁ  ned by a disease activity score in 28 joints (DAS28) 
<2.6, more stringent criteria may imply the absence of 
disease activity. The 2011 ACR/EULAR remission criteria 
provide the newest and most stringent deﬁ  nition of 
remission.  
  Objectives      To evaluate post hoc the remission by 
ACR/EULAR criteria and compare the criteria with the 
conventional DAS28 in TAMARA, an open-label phase 
IIIb tocilizumab (TCZ) trial including patients with active 
RA receiving inadequate disease-modifying antirheumatic 
drugs (DMARDs) or tumour necrosis factor α (TNFα) 
inhibitor treatment.   
  Results      286 patients were enrolled, 99.7% of patients 
were receiving a conventional DMARD and 41.6% had 
TNFα inhibitor pretreatment. Baseline mean DAS28 of 
6.0 ± 1.0 fell to 2.6 ± 1.5 at week 24. DAS28 <2.6 
was achieved by 47.6% at week 24. Remission rates with 
the new ACR/EULAR Boolean-based criteria for clinical 
studies were 15.0% after 12 weeks and 20.3% after 
24 weeks. Of note, 13.5% of patients with previous 
TNFα blocker inadequate response still achieved 
remission according to the new ACR/EULAR criteria after 
24 weeks. Clinical Disease Activity Index and Simpliﬁ  ed 
Disease Activity Index remission rates were 24.1% and 
25.2%, respectively.   
  Conclusions      Under the deﬁ  nition of the new stringent 
2011 ACR/EULAR remission criteria, patients with 
active RA despite DMARD treatment and even after 
inadequate response to TNFα inhibitors, receiving TCZ 
showed signiﬁ  cant rates of remission. Similar remission 
rates were achieved, when clinical practice criteria, not 
inclusive of acute phase reactants, were used.           
  INTRODUCTION 
  Remission as the primary therapeutic goal of 
rheumatoid arthritis (RA) treatment, was com-
monly deﬁ   ned by the disease activity score in 
28 joints (DAS28), with a DAS28 <2.6 indicating 
remission.  1    –    5   Clear limitations of the DAS28 have 
been recognised, as the DAS28 theoretically allows 
more than 10 swollen joints (SJs) for the deﬁ  nition 
of remission. Additionally, the erythrocyte sedi-
mentation rate (ESR) at low levels is overestimated 
by DAS28, and an increased ESR can also be caused 
by inﬂ   ammation processes independent of RA. 
Furthermore, DAS28 application in daily clinical 
practice may be hampered by the immediate need 
for the actual ESR result. The DAS28 cut-off point 
for RA remission of <2.6 has therefore been consid-
ered controversial.  6    –    11   
  Likewise based on 28-joint counts, both the 
Simpliﬁ  ed Disease Activity Index (SDAI) and the 
Clinical Disease Activity Index (CDAI) are more 
stringent for the deﬁ  nition of remission, because 
remission is limited to the appearance of a maxi-
mum of three and two SJs or tender joints (TJs), 
respectively. Recently, the ACR and EULAR in a 
joint effort presented new and even more stringent 
criteria for RA remission, suggesting criteria for 
clinical trials and for clinical practice. At any time 
point, a patient in a clinical trial must achieve a ten-
der joint count (TJC) ≤1, a swollen joint count (SJC) 
≤1, C-reactive protein (CRP) ≤1 mg/dl, a patient 
global assessment (PGA) ≤1, or, as an index- based 
score, an SDAI ≤3.3, to be considered in remission. 
For clinical practice, CRP was omitted and a CDAI 
≤2.8 replaced the SDAI.  12   
  Recently, the results of the phase IIIb study 
TAMARA were published.  13   The purpose of our 
analysis was to compare the high percentage 
of patients achieving DAS28 remission (47.6%) 
while receiving tocilizumab (TCZ) with the more 
stringent 2011 ACR/EULAR criteria. This may 
be particularly important when using a therapeu-
tic agent with a signiﬁ  cant inﬂ  uence on the acute 
phase response, such as the interleukin 6-receptor-
  inhibiting antibody TCZ.   
  PATIENTS  AND  METHODS 
  Details of the study have been described in detail else-
where.  13   Brieﬂ  y, in this multicentre, open-label, non-
controlled, single-arm study 286 patients with active 
RA (DAS28 >3.2) despite a stable dose of conven-
tional DMARD (cDMARD) or biological DMARDs 
were treated with 8 mg/kg TCZ (RoActemra) at 
4-weekly intervals for 24 weeks in addition to their 
cDMARD. One hundred and nineteen patients 
(41.6%) with mean disease duration of 10.5±7.5 
years (median 8.8) had been pretreated with tumour 
necrosis α factor (TNFα) antagonists. Patients pre-
treated only with cDMARDs had a shorter disease 
duration (mean 5.9±5.9 years (median 4.3)). Two 
hundred and thirty-nine patients (83.6%) completed 
the full 24 weeks of the trial.   The primary objective 
was to determine the proportion of patients reach-
ing lowDAS <3.2 after 24 weeks, secondary end 
points comprised the proportion of patients show-
ing a DAS28 remission (<2.6). For this analysis, we 
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assessed remission with the novel ACR/EULAR criteria,  12   compar-
ing them with DAS28 remission. The wording of the PGA Visual 
Analogue Scale (VAS) followed the more open DAS28 wording, 
in some contrast to the ACR/EULAR deﬁ  nition, which asks for 
speciﬁ  c arthritis complaints. Thus, the DAS PGA value had to be 
used as an estimate for the correct values, which might lead to 
underestimating Boolean rates of ACR/EULAR remission. The last 
observation carried forward method was used to impute missing 
values for continuous core variables. For categorical variables miss-
ing values were assessed as patients not reaching remission.   
  RESULTS 
  A total of 53.4% of patients with disease-modifying antirheu-
matic drug-inadequate response (DMARD-IR) RA and 41.2% of 
patients with TNFα-IR RA achieved DAS28 remission (details 
are published in Burmester   et al    13  ). 
  In addition to its pronounced effect on acute phase   reactants 
(APRs), the SJC and the TJC both decreased considerably. 
Compared with the reduction of the APR the effect on the SJC 
and the TJC was even more pronounced (see  ﬁ  gure 1A   and online 
supplementary table 1). While most patients in DAS remission 
had no SJs, approximately one in ﬁ  ve patients still had at least 
one, and up to six SJs (  ﬁ  gure 1B  ).     
Based on that observation, we assessed remission with the 
new ACR/EULAR Boolean based remission criteria of patients 
in clinical trials, deﬁ  ned as described above, allowing only a 
maximum of one TJ and one SJ. Applying these stringent cri-
teria, 16.1% of patients were in remission after 12 weeks and 
20.3% after 24 weeks (Figure 2a). Of note, when clinical practice 
deﬁ  nitions of remission (non-inclusive of APR) were employed, 
TCZ achieved remission in 15.0% of patients after 12 weeks 
and 20.3% after 24 weeks. While remission was achieved in 
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 Figure  1        (A) Twenty-eight joint count Disease Activity Score (DAS28) values of the patients reaching DAS remission at week 24. Each stacked bar 
represents the DAS28 value at the respective visit. Each segment of a single bar represents the proportion of DAS28 that is due to a speciﬁ  c core 
variable. In the ﬁ  gure it is, for example, shown that 2.3 points of a total DAS28 of 5.7 at baseline is due to erythrocyte sedimentation rate (ESR) or 
0.1 points of a total DAS28 of 1.5 is due to swollen joints (SJs) after 24 weeks. The relative reduction between baseline and week 24 is highest for 
swollen joint count (SJC) and tender joint count (TJC) (87.5% and 83.5%) compared with reduction of the ESR (65.2%). It is obvious that the TJC 
and the ESR are weighted higher in the DAS composite than the SJC and the Visual Analogue Scale (VAS). (Please note: numbers in the ﬁ  gure were 
rounded incorrectly for ESR at week 4 and 24, thus resulting in slightly different numbers.) (B) Number of patients, who are in DAS28 remission (grey) 
or and with a DAS >2.6 (black) after 24 weeks and their number of SJs. Though most patients in DAS28 remission had no SJs, some patients still 
had a signiﬁ  cant number of SJs.       
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over a quarter of patients (27.6%) pretreated with DMARDs, 
13.5% of patients with previous TNFα blocker IR still attained 
remission according to the new ACR/EULAR criteria after 24 
weeks. The CDAI and SDAI were slightly higher in the overall 
group (24.1% and 25.2%). 
  To assess whether the more stringent remission criteria had 
an impact on patient-related outcomes, we analysed the rela-
tionship with the Health Assessment Questionnaire-Disability 
Index (HAQ-DI), Functional Assessment of Chronic Illness 
Therapy-Fatigue (FACIT-fatigue) and pain scores after 24 weeks. 
The proportion of patients with an HAQ-DI of <0.5 was higher 
in patients reaching remission according to the new stringent 
criteria than in patients in DAS28 remission (see   ﬁ  gure 3A  ). 
Similarly, improvement in other patient-related outcomes was 
higher in patients in CDAI or SDAI remission than in patients in 
DAS28 remission. Nevertheless, patients with low disease activ-
ity according to CDAI, SDAI and DAS28 still beneﬁ  ted signiﬁ  -
cantly (  ﬁ  gure 3B  ).     
  DISCUSSION 
  The new remission criteria proposed by ACR and EULAR will 
probably replace the well-established DAS28-based criteria, 
which have always been controversial. It now remains to be 
established, if the novel criteria are indeed more useful in tri-
als, which try to model routine clinical practice. The TAMARA 
phase IIIb study appears to be suitable for analysing this ques-
tion. This trial had demonstrated very high rates of DAS28 
remission of 47.6% with TCZ, while the ESR fell from 28 mm/h 
to 6 mm/h. Cytokine-blocking biological agents, and TCZ in 
particular, led to a normal APR in almost all patients. While this 
constitutes a positive treatment effect, such improvement in 
ESR might lead to an overestimation of remission rates achieved 
with the DAS28.  14   The novel ACR/EULAR remission criteria are 
not prone to lead to such bias. However, given that they will not 
allow for more than one TJ or a VAS >1, remission deﬁ  ned by 
these criteria might be very difﬁ  cult to achieve. 
  When now analysing the same patient population with 
these new remission criteria, it came as no surprise that the 
more stringent remission criteria gave signiﬁ  cantly lower rates. 
Nevertheless, TCZ still achieved ACR/EULAR remission in more 
than a quarter of those patients who had not had an adequate 
response to cDMARDs, and in 13.5% of patients with active 
RA despite TNFα inhibitor failure. Moreover, 7% were in ACR/
EULAR remission as early as 4 weeks after starting TCZ. 
  The difference between the numbers for DAS28 and for 
ACR/EULAR remission was to be expected, given the narrow 
limits of one clinically SJ and TJ each and the ≤1 cm limit in 
patient self-assessment. However, these numbers indicate that 
ACR/EULAR remission is a meaningful concept and an attain-
able goal for clinical trials and clinical practice. Indeed, the new 
criteria showed better discrimination between RA refractory to 
cDMARDs and also not responding to TNF blockers. On the 
other hand, it was also reassuring to see that modern agents like 
TCZ now regularly achieve a more stringently deﬁ  ned remis-
sion despite inadequate response to DMARDs, and even TNFα 
blockers—that is, in a subset of patients for whom very few 
options would have existed 15 years ago. 
  CDAI and SDAI remission rates, the proposed indexed-
based remission criteria,  12   were closely linked in our study 
population, despite the inﬂ  uence of the CRP on SDAI, in view 
of the absence of APRs in CDAI. This is well in line with 
CDAI derivation data based on other DMARDs  15   and with 
ﬁ  ndings from the TCZ pivotal trials.  14   The fact that scores 
without ESR or CRP worked in the TAMARA trial, as well as 
the moderate weight of ESR changes between active disease 
and DAS28 remission (  ﬁ  gure 1  ) suggest that the reduction of 
the APR is not the decisive factor in leading to remission with 
TCZ. Our results suggest that the CDAI (without the APR) is 
sufﬁ  cient for the follow-up of patients receiving TCZ, because 
virtually all patients treated with TCZ have a normal CRP 
and/or ESR. 
  In comparison with the novel Boolean criteria, CDAI and 
SDAI are, however, somewhat more ﬂ  exible in their attribu-
tion of points. A patient with a global self-assessment of disease 
activity of 2.5 cm on the 10 cm scale may still be in CDAI remis-
sion, when SJC and TJC are zero. Most probably, the somewhat 
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 Figure  2     (A)Patients achieving remission according to the different assessment tools DAS28 ((0.56×TJC2) + (0.28×SJC2) + (0.7×ln (ESR)) + 
(0.014 × PtGA)<2.6) and the new ACR/EULAR criteria for clinical practice (Boolean-criteria SJC, TJC, PtGA all ≤1) and CDAI (SJC + TJC + PhGA + 
PtGA) ≤2.8) and clinical trials (Boolean-criteria SJC, TJC, PtGA, CRP all ≤1 and SDAI (SJC+ TJC + PhGA + PtGA + CRP (mg/dl)) ≤3.3 ). (B) Patients 
achieving low disease activity (DAS >2.6 and ≤3.2; CDAI >2.8 and ≤10; SDAI >3.3 and ≤11). (All data shown ‘as observed’). CRP, C-reactive 
protein; CDAI, Clinical Disease Activity Index; DAS28, 28-joint count Disease Activity Score; ESR, erythrocyte sedimentation rate; PhGA, physician 
global assessment; PtGA, patient global assessment; SDAI, Simpliﬁ  ed Disease Activity Index; SJC, swollen joint count; TJC, tender  joint  count.    
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higher remission rates with these scores are explained by such 
higher ﬂ  exibility. 
  ‘True’ remission may not have been achieved in many of the 
patients in DAS28 remission, and those who do not achieve 
remission according to the new ACR/EULAR criteria, in particu-
lar. Nevertheless, it is not entirely clear that these latter patients 
will not likewise have an excellent outcome. Although DAS28 
remission may not always be sufﬁ   cient to protect patients 
receiving methotrexate from structural damage,  12   the direct 
effects of biological response modiﬁ  ers both on the APR and 
on joint destruction may offer additional protection. Still, the 
improvement in the patient-related outcomes HAQ-DI, pain 
and fatigue was more pronounced in patients in CDAI or SDAI 
remission than in those in DAS28 remission, while reaching low 
disease activity was already associated with obvious beneﬁ  t 
(    ﬁ  gure 3A  ,  B  ). 
  Even low disease activity may be an acceptable result for some 
patients (especially those with   longstanding RA), and, on a con-
ciliatory note, the overall percentages of patients achieving at 
least low disease activity are virtually identical between DAS28, 
SDAI, and CDAI (see   ﬁ  gure 2B  ). This will cover approximately 
two out of three patients, while one-third of the patients still 
need a better individual treatment strategy.     
Our study has some limitations: this assessment with the 
new remission criteria is a post hoc analysis. The predeﬁ  ned 
outcome of the study was low disease activity and remission 
according to DAS28. In consequence, the wording of the patient 
VAS was more open, while the ACR/EULAR criteria suggest 
concentration on arthritis complaints. This may underestimate 
the Boolean rate of remission. TAMARA was an open-label, 
one-arm trial, which could increase both investigator bias and 
placebo effect. This might lead to an overestimate of remission 
rates. Moreover, the trial had a duration of 6 months only, and 
radiographic change was not assessed. 
  Nevertheless, to the best of our knowledge, this is the ﬁ  rst 
report using the new 2011 ACR/EULAR remission criteria for 
patients from a phase IIIb study receiving TCZ. The new crite-
ria have been validated in clinical trials with TNFα blockers  16    –    18   
showing remission rates in 22% of patients with early RA (data 
in Felson   et al     12  ). Such clinical trials, where patients meet strin-
gent inclusion criteria, differ from real-life medical care.  19   Our 
data from the TAMARA study, which was designed to reﬂ  ect 
daily clinical routine, show even higher remission rates of up to 
27.6% of patients whose RA had not adequately responded to 
cDMARDs before. Achieving stringent and sustained remission 
in patients with RA remains an ambitious aim, even with the 
treatment options we now have available. However, the new 
ACR/EULAR criteria for assessing remission deﬁ  ne a realistic, 
but very ambitious level of disease control, which will push us 
further toward reaching ‘true remission’. The fact this may still 
be more difﬁ  cult to achieve for patients with longlasting dis-
ease once again underlines the importance of early and effective 
treatment in daily clinical practice.   
  CONCLUSIONS 
  Measurement of RA remission with DAS28 has been shown to 
be of limited usefulness for treatment with biological response 
modiﬁ  ers. The new 2011 ACR/EULAR criteria for remission 
provide a new tool to stringently deﬁ  ne remission of RA in tri-
als and in routine clinical practice. Despite the stringency of 
these criteria and the highly active disease of the patients in 
the TAMARA study with DMARD pretreatment, TCZ induced 
remission rates in over a quarter of patients. Of note, signiﬁ  cant 
 Figure  3      (A)Proportion of patients with HAQ-DI remission (<0.5) 
according to the ﬁ  ve remission criteria (erythrocyte sedimentation 
rate (ESR); clinical trial (CTR); clinical practice (CP)). (B) Impact of 
clinical remission according to DAS28, CDAI or SDAI on patient-related 
outcome HAQ-DI (scaled from 0 to 3, 0=no disability), FACIT-fatigue 
(higher scores indicate better quality of life) and pain (visual analogue 
scale 0=no pain, 100=worst pain) after 24 weeks. The more stringent 
criteria CDAI and SDAI tended to have a better patient-related outcome 
on the HAQ-DI and pain, but not in the FACIT fatigue score. Noteworthy 
also patients with low disease activity beneﬁ  ted clearly from tocilizumab 
treatment. CDAI, Clinical Disease Activity Index; DAS28, 28-joint count 
Disease Activity Score; FACIT, Functional Assessment of Chronic Illness; 
HAQ-DI, Health Assessment Questionnaire-Disability Index; SDAI, 
Simpliﬁ  ed Disease Activity Index.       
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remission rates with TCZ were even achieved after inadequate 
response to TNFα inhibitors and also with disease activity 
measures not inclusive of APRs such as the CDAI and the new 
ACR/EULAR criteria for clinical practice. Cytokine blocking 
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agents, such as TCZ, can rapidly achieve stringent remission 
after DMARD (and TNFα blocker) failure. Thus, the new ACR/
EULAR remission criteria are feasible and produce meaningful 
numbers in settings close to everyday clinical routine.     
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